Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors

David A. RizzieriDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USACorrespondence[email protected]

Christopher CroutDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Robert StormsDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Jared GolobDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Gwynn D. LongDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Cristina GasparettoDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Keith M. SullivanDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Mitchell HorwitzDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

John ChuteDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Anand S. LagooDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Ashley MorrisDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Anne BeavenDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Yiping YangDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Bercedis PetersonDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Zhiguo LiDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

Nelson J. ChaoDepartment of Medicine, Division of Cellular Therapy, Department of Pathology, Department of Immunology, Department of Bioinfomatics and Biostatistics, Duke University Medical Center, Durham, North Carolina, USA

show all

Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date